Skip to content

A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00028353
Enrollment
500
Registered
2001-12-24
Start date
2001-04-30
Completion date
2003-07-31
Last updated
2013-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Intraepithelial Neoplasia

Keywords

PIN, High Grade Prostate Intraepithelial Neoplasia (PIN)

Brief summary

If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study. This is a study of an investigational medication that may reduce high grade PIN and prevent the occurrence of prostate cancer. This study is currently enrolling up to 500 men at approximately 60 locations in the United States.

Detailed description

High grade PIN is the development of precancerous, abnormal tissue of the prostate gland that puts men at high risk of developing prostate cancer. This study will take one year of participation with clinic visits every three months. There will be two prostate biopsies during the study, at six and twelve months. If qualified to participate, you will be randomly assigned to one of four treatment groups. Three out of four groups are varying doses of the study medication and the other is the placebo group (like a sugar pill).

Interventions

DRUGGTX-006 (Acapodene)

Sponsors

GTx
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
MALE
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must have confirmed high grade PIN on prostate biopsy within past 6 months. * Must have a serum PSA \<12 ng/ml. * Can not have prostate cancer. * Have significant ocular opacities. * Can not take finasteride or other testosterone like supplement.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026